We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
News

BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications

BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
News

BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioDuro will provide integrated research services in the areas of discovery chemistry, discovery biology, ADMET*, and DMPK** services, to help enhance internal drug discovery and shorten development timelines.


"After a successful collaboration involving discovery chemistry, ADMET, and DMPK, AstraZeneca has expanded its collaboration with BioDuro to leverage the strengths of its team to help develop new therapeutics," said Lena Martensson Director of Strategic Planning and Business Development.


"BioDuro is pleased to build upon this existing collaboration and work closely with the experienced team at AstraZeneca to develop new clinical compounds for Respiratory and Inflammation indications. This partnership demonstrates the strength of our innovation, quality, and our fully integrated R&D service platform," commented John Oyler, Chief Executive Officer and co-founder of BioDuro LLC.

 

Advertisement